PATENT CLAIM ANALYSIS

Application Number: 15905902
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "218000"]

Abstract:
There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.

Claim (Index 15):
The kit of  claim 13 , wherein the prostaglandin is latanoprost.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 88.0
- Lexical Diversity: 1.78378
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['11995052', '11993101', '14517509', '13004380', '15387113']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7669694639562558
- 35 USC 102 Novelty (BERT): 0.5115433153117965
- Combined Prediction Score: 0.7414268490918099
- Mean Citation Score: 252.645426
- Max Citation Score: 281.53128
- Similarity Product: 202.20201553549285

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test